Firma Ewopharma, Autor bei Presse-Blog

Ewopharma and Purpose Pharma Announce a Strategic Partnership for the Commercialization of Attrogy in Selected Central and Eastern European Countries

12. Oktober 2026 Firma EwopharmaAllgemeinAttrogy, Central and Eastern European, commercial partnership, commercialization, cross-border distribution, European Medicines Agency approval, medical commercialization, neurological disorders, neuropathy treatment, orphan drug strategy, patient access expansion, rare disease portfolio, rare diseases, specialty pharmaceuticals, strategic collaboration

Ewopharma is pleased to announce that it has entered into a strategic collaboration with Purpose Pharma for the commercialization of Attrogy® (diflunisal) in selected Central and Eastern European (CEE) countries. The partnership aims to expand patient access to this important Mehr

Ewopharma and Protina – Strengthening the Presence of Diasporal® and Basica® in Bulgaria with a new partnership

7. Juli 2026 Firma EwopharmaAllgemeinbasica, company, diasporal, ewopharma, flaschker, market, mineral, network, new, organic, production, protina, research, strong, with

Ewopharma AG and Protina Pharmazeutische GmbH announce their new distribution partnership for Bulgaria. Ewopharma takes over market access and the targeted promotion of Protina’s brands Diasporal® and Basica® – two consumer health brands already established in Bulgaria. Building on its Mehr

Ewopharma and Dr. Falk Pharma renew their long-standing partnership – a commitment built to last

29. Mai 2026 Firma EwopharmaAllgemeinboard, clinical, company, disease, ewopharma, falk, freiburg, health, market, network, new, patients, research, strong, with

Ewopharma AG and Dr. Falk Pharma GmbH are extending their distribution partnership of more than 27 years – for many more to come. Under the renewed distribution agreement, Ewopharma continues to manage market access and the targeted promotion of Dr. Mehr

Sugemalimab Receives I, A Recommendation in ESMO Guideline for Consolidation Therapy in Patients with Stage III NSCLC

16. April 2026 Firma EwopharmaAllgemeincancer, cell, cells, cstone, egfr, esmo, ewopharma, market, monotherapy, nsclc, patients, ros1, sugemalimab, tumour, with

Ewopharma is pleased to report that sugemalimab, licensed from partner CStone Pharmaceuticals, has received a I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. This recommendation supports sugemalimab for Mehr

Sugemalimab Achieves New Regulatory Milestone: European Commission Approves Stage Ⅲ NSCLC Indication

17. Dezember 202522. Dezember 2025 Firma EwopharmaAllgemeinalk, cancer, cell, cells, chemoradiotherapy, cstone, egfr, ewopharma, monotherapy, nsclc, patients, ros1, sugemalimab, tumour, with

Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CStone Pharmaceuticals. In late November 2025, the European Commission (EC) granted approval for a new indication for sugemalimab as monotherapy for adult patients with Mehr

Ewopharma AG Announces Exclusive Distribution Agreement for Cardiovascular Solutions in Bulgaria

15. April 202511. April 2025 Firma EwopharmaMedizintechnikballoon, coatings, dcb, eluting, ewopharma, healthcare, market, medical, patients, restenosis, solutions, translumina, treatment, vessel, with

Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and Blue Medical’s drug-coated balloon (DCB) technologies in Bulgaria. The agreement includes two key categories of interventional cardiovascular solutions: Drug-Eluting Stents – The DES Mehr

AllergyCare AG Becomes Part Of Ewopharma Group

3. Juni 20243. Juni 2024 Firma EwopharmaAllgemeinaida, business, company, customers, ewopharma, health, healthcare, home, market, new, pharmaceutical, privileged, services, treatment, with

Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of AllergyCare AG, a Swiss distribution company of pharmaceutical and consumer health products with a focus on the prevention Mehr

Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland

27. Mai 202427. Mai 2024 Firma EwopharmaAllgemeincancer, cee, cell, clinical, ewopharma, lymphoma, medical, new, nsclc, patients, payment, research, revenues, treatment, with

Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovationdriven biopharmaceutical company focused on the research and development of anti-cancer therapies. Under the agreement, Ewopharma will gain the commercial rights Mehr

Neomed s.r.o. becomes part of Ewopharma Group

31. Mai 2023 Firma EwopharmaFirmeninterncompany, cosmetic, devices, ewopharma, healthcare, intraocular, lenses, logistics, market, medical, new, patients, pharmaceutical, services, with

Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Neomed s.r.o., a Czech Distribution company of pharmaceuticals, medical devices, and cosmetics. As part of a succession solution, Mehr

Ewopharma and Vianex announce collaboration to distribute the essential antibiotic Amikacin in Switzerland

29. Juli 201929. Juli 2019 Firma EwopharmaMedizintechnikamikacin, antibiotic, business, drugs, ewopharma, home, market, network, new, pharmaceutical, production, protein, treatment, vianex, with

Ewopharma and Vianex S.A. are pleased to announce their new partnership for distribution of Amikacin in Switzerland. Ewopharma will be the new market authorisation holder for the drug and assuming all responsibilities of the former distributor Bristol Myers Squibb. Amikacin Mehr

Autor: Firma Ewopharma